Clinical trials: Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Condition Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Funder type Industry (pharma, biotech, devices)
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).
- Trial name
- POLAR-A (NCT04034355)
- Testing
- Calmangafodipir (5 µmol/kg)
- Where
- 65 sites in Belgium, Czechia and 8 more
- Volunteers
- 301 people
- Sponsor
- Egetis Therapeutics AB (publ)
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN)
Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device
The goal of this clinical trial is to examine a low-intensity, low-risk cranial PEMF device and its effectiveness with helping cancer patients manage neuropathy symptoms from chemotherapy.
- Conditions
- Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT07061769
- Testing
- SHIFT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- FluxWear, INC
Chemotherapy-induced Peripheral Neuropathy (CIPN)
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy.
- Trial name
- NCT05435742
- Testing
- SON-080
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Sonnet BioTherapeutics
Chemotherapy Induced Peripheral Neuropathy (CIPN)
SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects
Randomized, double-bline, placebo-controlled, single dose study comparing the pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian) subjects.
- Trial name
- NCT03430999
- Testing
- Calmangafodipir
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Egetis Therapeutics AB (publ)
Chemotherapy-induced Peripheral Neuropathy
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in…
- Trial name
- ACT (NCT05593614)
- Testing
- ATX01 10%, ATX01 15%
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 276 people
- Sponsor
- AlgoTherapeutix
Peripheral Nervous System Diseases
A Study to Investigate the Safety and Efficacy of Ricolinostat
This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.
- Trial name
- NCT05229042
- Testing
- Ricolinostat
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.
- Trial name
- POLAR-M (NCT03654729)
- Testing
- Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg)
- Where
- 98 sites in United States, Belgium and 11 more
- Volunteers
- 291 people
- Sponsor
- Egetis Therapeutics AB (publ)
Cancer
A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A multicenter, phase IV, interventional study to assess the efficacy and safety of Targin (Oxycodone/Naloxone) Korean patients with CIPN (Chemotherapy-Induced Peripheral Neuropathy) who need opioid combination treatment with…
- Trial name
- NCT01675531
- Testing
- Targin
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Mundipharma Korea Ltd
Quality of Life (QOL), CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study for the Evaluation of the Degree of Skin Satisfaction of a Cosmetic Cream for Sensitive Skin in Oncological Patients Affected by a Palmoplantar Polyneuropathy Secondary to Chemotherapy.
It is proposed a controlled research study aimed to evaluating and comparing the degree of skin satisfaction and comfort with cosmetic creams PB-011 and PB-012 in cancer patients who can develop a palmar and plantar peripheral…
- Trial name
- NCT06733545
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- PROSPERA BIOTECH S.L.
Chemotherapy-induced Peripheral Neuropathy
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
The primary objective of the study is: to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy…
- Trial name
- NCT04282590
- Sponsor
- Toray Industries, Inc
Chemotherapy Induced Peripheral Neuropathy (CIPN)
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy.
- Trial name
- IMPACT (NCT07142304)
- Testing
- The Lilac Device
- Where
- 18 sites in United States, Ireland
- Volunteers
- 142 people
- Sponsor
- Luminate Medical, Inc.
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain
- Trial name
- NCT07072468
- Testing
- VMD-3866 Gel
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- VM Therapeutics LLC
Chemotherapy-induced Peripheral Neuropathy
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy.
- Trial name
- NCT07765446
- Testing
- SIR2501
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sironax USA, Inc.
CIPN in Adjuvant Colon Cancer Patients, CIPN in Adjuvant Breast Cancer Patients
Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy
The objective of this observational study is to evaluate the effectiveness of the dietary supplementation "OnLife" in improving signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adult patients who have…
- Trial name
- STEFANO (NCT03065478)
- Testing
- OnLife
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Swiss Medical Food AG
Chemotherapy-induced Peripheral Neuropathy (CIPN)
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with…
- Trial name
- NCT06860789
- Testing
- AK135
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Akeso
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections.
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Trial name
- NCT06848348
- Testing
- Halneuron, Halneuron (Open Label Extension)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dogwood Therapeutics Inc.
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of…
- Conditions
- Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
- Trial name
- SENSE (NCT04932031)
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sapere Bio
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
- Trial name
- NCT06538272
- Testing
- ONO-2910
- Where
- 30 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Chemotherapy-induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer…
- Trial name
- EPIPHANY (NCT03997981)
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Disarm Therapeutics